

Empowering Early Detection of Kidney Injury

2022-Q3 Financial Results & Business Update



November 9, 2022

Forward-Looking Statements

References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matter contained herein. By viewing or receiving or reading this presentation or attending any meeting where this presentation is made, you agree to be bound by the limitations, qualifications and restrictions set out below.

Certain statements in this presentation are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company’s expectations, intentions and projections regarding its future performance including the Company’s Guidance for 2022; currency exchange rate fluctuations; anticipated events or trends and other matters that are not historical facts, including with respect to the potential FDA marketing authorization, implementation of manufacturing and quality systems, commercialization of NGAL tests, and the development of future products and new indications; concerns that may arise from additional data, analysis or results obtained during clinical trials; and, the Company’s ability to successfully market both new and existing products. These forward-looking statements, which may use words such as “aim”, “anticipate”, “believe”, “intend”, “estimate”, “expect” and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company’s business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto’s success are more fully discussed in the sections captioned “Risk management” in BioPorto’s 2021 Annual Report and “Significant risks and uncertainties” in BioPorto’s Interim Reports.

This presentation is for information purposes only and does not constitute an offer to sell or a solicitation of any offer to buy any securities issued by the Company in any jurisdiction. The information contained herein is not for distribution in the United States of America. This document does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The Company’s securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold within the United States absent registration or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to offer or solicit an offer to buy any securities in the Company in the United States or to make a public offering of the securities in the United States. Company securities may be sold only to qualified institutional buyers (as defined in Rule 144A under the Securities Act) in reliance on Rule 144A.



Highlights from Q3 2022

- Data for FDA submission for the NGAL Test is being compiled and analyzed - subject to ongoing review, it remains on track for Q4 2022
- Solid financial performance - YTD revenue up 16% over 2021
- Controlled commercialization costs - modifying EBIT and Adjusted EBITDA guidance to reflect deferred commercialization expenses

We save lives and improve quality of life with actionable biomarkers

In 2022-2023 we will Launch an FDA Cleared Product in the US



Drive Market Adoption of the NGAL Test & have a Pipeline of Products that Deliver High Medical Value



Strengthen the Company to Scale & Execute



Attract, Develop & Retain the Best and Brightest Employees Aligned with our Values and with Clear Roles and Responsibilities

Go-To-Market approach will leverage regional resources of Partners

Core Services

- Licensing
- Product Development
- Regulatory Filings
- Intellectual Property
- Manufacturing



Global Market Access Services

- Medical Education
- HEOR Studies
- Market Development
- Reimbursement

Open Channel Model

- Sales force & contracting
- Stocking distributor
- Instrument validation assistance
- Customer support

Partner Channel Model includes above plus

- Private labeling
- Analyzer-specific cartridges/volumes
- Manufacturing

Engaged




In Discussion


- Other major lab analyzer manufacturers

Critical care-focused product development pipeline

New Product Development




Expanded Indications for The NGAL Test



AKI: Abrupt loss of kidney function


- Today, subclinical in its early stages
- Preventable and treatable if detected early, but 70% of clinicians believe they are missing AKI
- Often occurs in hospitalized patients, particularly those with critical illness
- Can lead to
 - Retention of waste products
 - Fluid dysregulation
 - Progressive kidney damage leading to kidney failure, multi-organ failure, and death



The NGAL Test saves lives by detecting AKI earlier

Empowers clinicians to manage fluids & nephrotoxic drugs, and determine if dialysis is needed

- NGAL: Neutrophil Gelatinase-Associated Lipocalin
- Critical care biomarker protein expressed in proximal and distal nephron tubules within the kidney
- Upregulated and detectable within 2-3 hours following ischemic or nephrotoxic injury to the kidney



Current method, Serum Creatinine (sCr), is delayed and non-specific

In a multicenter prospective study of over 500 biopsy-diagnosed cases of moderate to severe AKI, sCr only properly identified 26% of patients¹

Delayed and Dampened



Does not rise until 48-72 hours after acute injury



>50% of kidney function can be lost, without changes in sCr

Non-specific for AKI



Can't differentiate structural injury from volume-responsive AKI¹



Diluted by fluid overload, delaying AKI identification

Confounded by Other Factors



Muscle mass



Nutritional status



Age & gender

NGAL for differential diagnosis and therapy of cirrhosis patients with AKI¹

Published September 2022


- Cirrhosis can coincide with AKI and complicates diagnoses
- NGAL used to discriminate different etiologies of AKI (Acute Tubular vs. Hepatorenal Syndrome Necrosis) in cirrhosis patients
- NGAL assisted in determining prognosis of terlipressin and albumin therapy for cirrhosis
- 59% of cirrhosis patients identified responded well to treatment

Conclusions

“ uNGAL is an excellent urinary biomarker in differential diagnosis between ATN-AKI and HRS-AKI and can play a significant role to refine the diagnosis of AKI in patients with cirrhosis.”

“ it is an independent predictor of in-hospital mortality.” ¹

Effective AKI intervention requires an early indication of kidney injury¹




¹AKI Therapeutics, Presented by P. Devarajan at the International Symposium on AKI for Children, 2 Oct 2022, citing Dong, Devarajan, Pediatric Nephrology 2017; 32:2351-2360. ²Currently undergoing clinical trials




BioPorto has grown revenue by 16% YTD over 2021

Revenue by Quarter



YTD Revenue by Product Group






NGAL test sales up 15% YTD over 2021

Global NGAL

↑ 15%

Growth in global YTD NGAL test sales over 2021


NGAL test sales by Quarter (LTM, DKKm)





Solid cash position and working capital management

Adjusted EBITDA and cash position (DKKm)



- YTD'22 cash burn from operations: DKKm 35.9, a 29% reduction vs. YTD'21 from favorable working capital management
- Cash balance: DKKm 98.9

Guidance for 2022 adjusted to reflect timing of costs

Amounts in millions of Danish Kroner and US Dollars¹

2022 Guidance			Actual at Sept. 30, 2022
Revenue	DKK 24-27 \$3.1-3.5	EBIT loss DKK (83)-(88) [previously DKK (95)-(100)] \$(10.9)-(11.5)	Cash ² DKK 99 \$13.0
		Adj. EBITDA loss DKK (71)-(75) [previously DKK (76)-(81)] \$(9.3)-(9.8)	

¹All Financial Figures Converted from DKK to USD at a rate of 7.6287:1 as of September 30, 2022. ²Unaudited.

Note: BioPorto's performance and guidance for 2022 is based on certain assumptions described in the annual and interim report(s) and continues to be subject to uncertainty due to COVID-19, including continued opening of societies and the normalization of access to hospitals, research laboratories, and regulatory bodies. Please see the Company's 2021 Annual Report and Interim Reports for further information on risks and uncertainties.

Investment Thesis: The first meaningful Acute Kidney Injury (AKI) test



Clinicians are demanding and using The NGAL Test -- a better kidney injury diagnostic



The NGAL Test™ saves kidneys & lives with AKI detection when the injury is clinically silent



Serves a \$3B+ global Market Opportunity in AKI as a critical care immunoassay



FDA Breakthrough Designation received and on track for a **2022 De Novo Submission**



New leadership and Board with a record of successfully launching novel diagnostics and devices



Global, strategic, non-exclusive partnership with Roche Diagnostics

Investor Relations Contacts

CPH:BIOPOR

EU: Tim Eriksen
Managing Partner
Zenith Advisory
investor@bioporto.com
+45 4529 0000

US: Ashley Robinson
Managing Director
LifeSci Advisors
arr@lifesciadvisors.com
+1 617 430 7577